Connors Investor Services’s Catalyst Pharmaceutical CPRX Stock Holding History

Connors Investor Services’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-30,538	Closed	-$214K	–	153
2022 Q2	$214K	Sell	30,538 -5,000	-14%	-$36.7K	0.03%	133
2022 Q1	$295K	Sell	35,538 -9,000	-20%	-$63.6K	0.03%	128
2021 Q4	$302K	Sell	44,538 -15,000	-25%	-$98.6K	0.03%	126
2021 Q3	$316K	Hold	59,538	–	–	0.03%	127
2021 Q2	$342K	Hold	59,538	–	–	0.04%	122
2021 Q1	$274K	Hold	59,538	–	–	0.03%	131
2020 Q4	$199K	Buy	59,538 +18,000	+43%	+$60.5K	0.02%	136
2020 Q3	$123K	Buy	+41,538	New	+$162K	0.02%	130

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Connors Investor Services's CPRX Position: Q3 2022 in Review

Connors Investor Services sold out of Catalyst Pharmaceutical (CPRX) in Q3 2022, closing a stake of 30,538 shares — an estimated $214K sold.

Connors Investor Services first reported a position in CPRX in Q3 2020 and held it in 8 quarters. The position peaked at $342K in Q2 2021. 229 funds tracked by Wall St. Rank hold CPRX as of Q3 2022.

Connors Investor Services reported no remaining Catalyst Pharmaceutical position as of Q3 2022 after selling out during the quarter.
Connors Investor Services sold 30,538 Catalyst Pharmaceutical shares in Q3 2022, an estimated $214K.
Connors Investor Services first reported a position in Catalyst Pharmaceutical in Q3 2020 and held it in 8 quarters.
Connors Investor Services's Catalyst Pharmaceutical position peaked at $342K in Q2 2021.
229 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2022.

Based on Connors Investor Services's 13F filing for Q3 2022, filed 14 Nov 2022.